|
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
CDC25B, CXCL8, FZD6 and MCM4 were screened as candidate genes for prognosis assessment of patients with ESCC.
|
31748958 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that MCM2, MCM4 and MCM10 are potential prognostic markers and therapeutic targets for LUAD.
|
31545501 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Prognosis analysis in TCGA and KM plotter cohorts suggest that high abundance of MCM5, MCM8 and MCM4 notably correlated to poor LUAD overall survival.
|
31323040 |
2019 |
|
Eosinophil count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Survival analysis in the GSE14520 cohort suggested that expression of <i>MCM2, MCM4, MCM5,</i> and <i>MCM6</i> were significantly associated with hepatitis B virus-related HCC overall survival (OS).
|
30026832 |
2018 |
|
Colorectal Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The most promising of these candidate genes were: (i) PRKCA, PRKDC, and MCM4, as a functional relation to MSH2 is predicted by network analysis, and (ii) CSMD1, as this is commonly mutated in CRC.
|
29987844 |
2018 |
|
Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression levels of MCM2, MCM5, MCM6, and MCM7, but not of MCM3 and MCM4, were higher in RCC compared to paired adjacent normal tissue.
|
29180899 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression levels of MCM2, MCM5, MCM6, and MCM7, but not of MCM3 and MCM4, were higher in RCC compared to paired adjacent normal tissue.
|
29180899 |
2017 |
|
Laryngeal Squamous Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The results showed that siRNA of MCM4 could significantly inhibit LSCC cell line UMSCC 5 proliferation and induce apoptosis.
|
29135113 |
2019 |
|
Squamous cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The quantitative reverse transcriptase-polymerase chain reaction analysis verified the upregulation of ASAH1, PCBP2, DDX5, MCM5, TAGLN2, hnRNPA1, ENO1, TYPH, CYC, and MCM4 in squamous cell carcinoma compared to normal cervix ( p < 0.05).
|
28443473 |
2017 |
|
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Mean Corpuscular Volume (result)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Liver carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The HCC risk was lower in patients with the MCM4 rs2305952 CC (OR = 0.22, 95%CI: 0.08-0.63, P = 0.01) and with the CHEK1 rs515255 TC, TT, TC/TT (OR = 0.73, 95%CI: 0.56-0.96, P = 0.02; OR = 0.67, 95%CI: 0.46-0.97, P = 0.04; OR = 0.72, 95%CI: 0.56-0.92, P = 0.01, respectively).
|
27350734 |
2016 |
|
Malignant tumor of cervix
|
0.020 |
Biomarker
|
disease |
BEFREE |
HPV-type-specific response of cervical cancer cells to cisplatin after silencing replication licensing factor MCM4.
|
26188903 |
2015 |
|
Cervix carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
HPV-type-specific response of cervical cancer cells to cisplatin after silencing replication licensing factor MCM4.
|
26188903 |
2015 |
|
cervical cancer
|
0.020 |
Biomarker
|
disease |
BEFREE |
HPV-type-specific response of cervical cancer cells to cisplatin after silencing replication licensing factor MCM4.
|
26188903 |
2015 |
|
Nasopharyngeal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
has-miR-615-3p might take part in the pathogenetic process of NPC through regulating MCM4 which is enriched in cell cycle.
|
25973099 |
2015 |
|
Malignant neoplasm of skin
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
G364R mutation of MCM4 detected in human skin cancer cells affects DNA helicase activity of MCM4/6/7 complex.
|
25661590 |
2015 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Among these, MCM4, 6 and 10 show increased frequency of over expression along with advancement of tumor stages.
|
23874974 |
2013 |
|
Malignant tumor of cervix
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
MCM4, 5 and 6 also show differential expression in different types of lesion, while MCM2 and MCM10 are over expressed in cervical cancer irrespective of clinico-pathological parameters.
|
23874974 |
2013 |
|
Cervix carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
MCM4, 5 and 6 also show differential expression in different types of lesion, while MCM2 and MCM10 are over expressed in cervical cancer irrespective of clinico-pathological parameters.
|
23874974 |
2013 |
|
cervical cancer
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
MCM4, 5 and 6 also show differential expression in different types of lesion, while MCM2 and MCM10 are over expressed in cervical cancer irrespective of clinico-pathological parameters.
|
23874974 |
2013 |
|
Aarskog syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
Novel gene defects in FGD have recently been recognised in mini-chromosome maintenance-deficient 4 homologue (MCM4) and nicotinamide nucleotide transhydrogenase (NNT).
|
23392095 |
2013 |
|
Aarskog syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
Recently mutations in mini chromosome maintenance-deficient 4 homologue (MCM4) and nicotinamide nucleotide transhydrogenase (NNT), genes involved in DNA replication and antioxidant defence respectively, have been recognised in FGD cohorts.
|
23279877 |
2013 |